Medication Assisted Treatment. Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs
|
|
- Nathaniel Webb
- 5 years ago
- Views:
Transcription
1 Medication Assisted Treatment Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs
2 Disclosures Employed by the Department of Veterans Affairs (VA) No commercial financial conflicts of interest May discuss uses of medications that are not FDA-approved indications. For example: Topiramate and gabapentin for treatment of alcohol use disorder
3 LEARNING OBJECTIVES The participant will be able to: Understand the rationale for using medications to treat substance use disorders Understand the risks and benefits of different medications for treatment of withdrawal from: Alcohol Opioids Understand the risks and benefits of different medications for treatment of: Alcohol use disorder Opioid use disorder
4 OVERVIEW Why medications? Specific medications: Alcohol Opioids
5 WHY MEDICATIONS? SUDs are chronic brain diseases Multifactorial, like other chronic diseases Respond best to comprehensive treatment Require long-term treatment Medications improve treatment outcome over psychosocial interventions alone Facilitate engagement in psychosocial treatment Reduce craving and risk of relapse Protect against opioid overdose
6 Raising Awareness Since 1999, opioid pain medicine prescriptions quadrupled without any change in Americans report of pain. From 1999 to 2015, the number of opioid-related overdose deaths quadrupled. On average, 91 Americans died of opioid overdose every day.
7 AS OPIOID SALES INCREASED, SO HAS OPIOID USE DISORDER AND OVERDOSE DEATHS eview/mmwrhtml/mm6043a4. htm July 11,
8 DSM-5 Criteria- Opioid Use Disorder DSM-5 Criteria (2 or more of the following criteria) Craving or strong desire to use opioids Recurrent opioid use in hazardous situations Using more opioids than intended Persistent desire/unable to cut down or control opioid use Great deal of time spent obtaining, using or recovering from the effects Continued opioid use despite persistent opioid-related social problems Continued opioid use despite opioid-related medical or psychological problem Failure to fulfill role obligations in order to use opioids Important activities given up in order to use opioids *Tolerance (requiring at least 50% more to achieve desired effect) *Characteristic withdrawal (e.g. dilated pupils, rhinorrhea, diarrhea, piloerection, muscle cramps, increased pain sensitivity)
9 SUBSTANCE USE DISORDERS (SUDS) SUDs are chronic brain diseases SUDs respond best to chronic disease management Diabetes/hypertension Diet/exercise for all Medication for most Specialty care for those with complex needs July 11,
10 Opioid Effect Pain/ dysphoria Euphoria OPIOID EFFECT SINGLE DOSE 10
11 Opioid Effect Pain/ dysphoria Euphoria MULTIPLE DOSES LEAD TO TOLERANCE 11
12 MAT MECHANISMS OF ACTION Agonist Opiates-opium, morphine, heroin, codeine, oxycodone, hydrocodone Synthetic opioids- methadone, fentanyl Partial agonist Buprenorphine Antagonist Naloxone Naltrexone DATE DOCUMENT TYPE/STATUS 12
13 Opioid Effect Dysphoria Euphoria SIMPLIFIED MECHANISM OF ACTION Methadone Buprenorphine Heroin Naltrexone 13
14
15 EVIDENCE HIERARCHY Metaanalyses of RCTs Randomized Controlled Trials Observational Studies Non Analytical Studies Expert Opinion Recommendations are explicitly linked to the supporting evidence and graded according to the strength of that evidence
16 PATIENT CENTERED CARE: BEGINS WITH SHARED DECISION MAKING Patient is the expert on his/her life and experience. Elicit preferences and goals Strengths and weaknesses Clinicians are expert on risksbenefits of the full menu of treatment options. Provide easily understandable information for patients to make an informed decision Collaborate to develop treatment goals/objectives/interventions. Assess progress and modify the plan, as indicated.
17 TREATMENT: OPIOID USE DISORDER Medications We recommend: Buprenorphine/ naloxone (OBOT or OTP) Methadone (in an OTP) If buprenorphine/naloxone or methadone are not acceptable, we recommend: ER-injectable naltrexone Buprenorphine (without naloxone for pregnant patients) Psychosocial Interventions At the start of OBOT, we recommend: Addiction-focused Medical Management Other interventions as indicated In an OTP, we suggest: Individual Drug Counseling and/or Contingency Management For patients for whom OUD medication is unacceptable or unavailable, there is insufficient evidence to recommend for or against any specific psychosocial interventions.
18 MEDICATION FOR OPIOID USE DISORDER (OUD)
19 BUPRENORPHINE VERSUS METHADONE Buprenorphine/naloxone Methadone Treatment setting? Any Specially licensed OTP Mechanism of action Partial opioid agonist Full opioid agonist FDA approved for OUD? Yes Yes Reduces opioid craving? Yes Yes Improves treatment retention? Yes Yes, better than buprenorphine Reduces mortality? Yes Yes, but first month carries higher risk than maintenance phase Recommended for OUD candidates with anticipated need for opioid pain medicine? No Yes, with caution
20 EXTENDED RELEASE INJECTABLE NALTREXONE
21 ADDICTION-FOCUSED MEDICAL MANAGEMENT
22 Close Monitoring & Brief Counseling May Be Sufficient 24-wk RCT in Primary Care (n=141) Physician Management (PM) is 15 min structured counseling by MD x 24 wks. Weekly tapering to monthly CBT-SUD is weekly individual therapy PM +/- CBT-SUD 12- weeks with: Almost 80% retention 4-5 weeks of consecutive abstinence Fiellin et al: Am J Medicine Fiellin et al- Am J Medicine 22
23 BUPRENORPHINE MAINTENANCE IMPROVES ODDS OF SUCCESSFUL RECOVERY 10-FOLD Phase 2 Time Point Observed, No./Total No. (%) [95% Confidence Interval (CI)] End of treatment 177/360 (49.2) [ ] 8-week posttreatment follow-up 31/360 (8.6) [ ] Odds Ratio (95% CI) P Value 10.6 ( ) <0.001 Weiss R et al: 2011;Arch Gen Psych 23
24 TREATMENT: ALCOHOL USE DISORDER Medications We recommend: Acamprosate Disulfiram Naltrexone- oral or injectable Topiramate If first-line medication is unacceptable, we suggest: Gabapentin Psychosocial Interventions We recommend: Behavioral Couples Therapy for alcohol use disorder Cognitive Behavioral Therapy for substance use disorders Community Reinforcement Approach Motivational Enhancement Therapy 12-Step Facilitation For patients in early recovery, we recommend promoting active involvement in group mutual help: Peer linkage Network support 12-step facilitation
25 Medication Assisted Treatment (MAT) Reduces Mortality for Those with OUD Retention in methadone and buprenorphine treatment is associated with reduced overdose and all-cause mortality. The first 4 weeks of methadone induction and the first month after discontinuing either medication is associated with higher mortality Sordo et al-bmj Open 25
26 Oral Naltrexone for Alcohol Use Disorder Volpicelli et al: 1992 Arch Gen Psych 49(11):876-80
27 Oral Naltrexone Reduces Relapse to Heavy Drinking 27
28 XR-Naltrexone Injection Associated with Reduced Mortality and Hospital Readmissions Outcome measure 1 year mortality Odds Ratio for NTX-XR/control 0.30 (p < 0.001) In subset with detox in prior year Subsequent detox episodes 1 year mortality 0.80 (p < 0.001) 0.78 (p < 0.001) Case-Control design 387 veterans with AUD received extended-release injectable naltrexone (NTX-XR) 3759 controls Propensity score weighted, mixed-effects logistic regression model for 1-year mortality. For subset with at least one detox episode in previous year, # detox episodes in following year. Harris et al Alcohol Clin Exp Res-39:
29 Efficacy of Disulfiram in Blinded versus Open-Label Trials 2014-Skinner et al-plos One 2014 g= 0.70
30 Efficacy of Supervised versus Unsupervised Disulfiram 2014-Skinner et al-plos One 2014 g = 0.82
31 Acamprosate Supports Abstinence in Alcohol Use Disorder Jonas et al: 31
32 Alcohol Care Management (ACM) Behavioral Health Lab 26 week randomized trial of ACM (medication and psychosocial support) in primary care clinic versus referral to SUD specialty care. Behavioral Health Provider (BHP) on Primary Care team delivers personalized, measurement-based SUD care. Motivational interviewing Patient education Action planning 32
33 CONCLUSIONS Substance use disorders are preventable and treatable chronic diseases Effective treatment is: Patient centered Evidence based Life sustaining Empowering a life worth living Accessible We all need to do our part to improve the health and safety of our Veterans 33
34 ACKNOWLEDGEMENTS VA Academic Detailing Service VA Office of Quality Safety & Value VA Program Evaluation and Resource Center at Palo Alto VAMC DATE DOCUMENT TYPE/STATUS 34
35 Questions 35
Treatment Alternatives for Substance Use Disorders
Treatment Alternatives for Substance Use Disorders Dean Drosnes, MD, FASAM Associate Medical Director Director, Chronic Pain and SUD Program Caron Treatment Centers 1 Disclosure The speaker has no conflict
More informationMedication-Assisted Treatment. What Is It and Why Do We Use It?
Medication-Assisted Treatment What Is It and Why Do We Use It? What is addiction, really? o The four C s of addiction: Craving. Loss of Control of amount or frequency of use. Compulsion to use. Use despite
More informationSubstance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates
Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates What is MAT? Medication Assisted Treatment (MAT) is the use of medications, in addition to counseling, cognitive behavioral
More informationOpiate Use Disorder and Opiate Overdose
Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5
More informationMark Edlund, MD, PhD RTI International. Photo courtesy of The Herb Museum, Vancouver, BC
Opioid Use Disorders and Their Treatment Mark Edlund, MD, PhD RTI International Photo courtesy of The Herb Museum, Vancouver, BC Acknowledgements Funded by NIDA R01 DA022560-01 NIDA R01 DA034627 NIDA R01
More information6/6/2018. Objectives. Outline. Rethinking Medication Treatment for Opioid Use Disorder
Rethinking Medication Treatment for Opioid Use Disorder International Conference on Opioids June 10, 2018 Dustin Patil, MD Fellow, Addiction Psychiatry Boston Medical Center John Renner, MD Professor of
More informationNORTHWEST AIDS EDUCATION AND TRAINING CENTER. Opioid Use Disorders. Joseph Merrill M.D., M.P.H. University of Washington April 10, 2014
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Opioid Use Disorders Joseph Merrill M.D., M.P.H. University of Washington April 10, 2014 Opioid Use Disorders Importance of opioid use disorders Screening and
More informationShawn A. Ryan MD, MBA President & Chief Medical Officer Board Certified, Addiction Medicine
[Patient-focused, evidence-based addiction treatment] Shawn A. Ryan MD, MBA President & Chief Medical Officer Board Certified, Addiction Medicine BrightView Health All Rights Reserved www.brightviewhealth.com
More informationAn overview of Medication Assisted Treatment (MAT) and acute pain management on MAT
An overview of Medication Assisted Treatment (MAT) and acute pain management on MAT Goals of Discussion Recognize opioid use disorder (OUD) Discuss the pharmacology of medication assisted treatments (MAT)
More informationOpioid Use in Youth. Amy Yule M.D. March 2,
Opioid Use in Youth Amy Yule M.D. March 2, 2018 An opioid is a substance that acts on opioid receptors Beta-endorphin Endogenous opioids Dynorphin Opiates Natural products of the poppy plant Morphine Heroin
More informationThe role of behavioral interventions in buprenorphine treatment of opioid use disorders
The role of behavioral interventions in buprenorphine treatment of opioid use disorders Roger D. Weiss, MD Harvard Medical School, Boston, MA, McLean Hospital, Belmont, MA, USA Today s talk Review of studies
More informationSerious Mental Illness and Opioid Use Disorder
Serious Mental Illness and Opioid Use Disorder Serious Mental Illness and Opioid Use Disorders Arthur Robin Williams, MD MBE Columbia University, Department of Psychiatry Nick Szubiak, MSW, LCSW Director,
More information2/21/2018. What are Opioids?
Opioid Crisis: South Carolina Responds Carolyn Bogdon, MSN, FNP-BC Coordinator for Emergency Department Medication Assisted Treatment Program Medical University of South Carolina Opioid Crisis: A Mounting
More informationOpioid Use Disorder Treatment Initiation in Diverse Settings
Opioid Use Disorder Treatment Initiation in Diverse Settings Sarah Wakeman, MD, FASAM Medical Director, Mass General Substance Use Disorder Initiative Assistant Professor, Harvard Medical School Disclosures
More information2/19/18. Today s talk. Today s talk. The Role of Behavioral Interventions in Buprenorphine Treatment of Opioid Use Disorders
The Role of Behavioral Interventions in Buprenorphine Treatment of Opioid Use Disorders Roger D. Weiss, MD Chief, Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, MA Professor of Psychiatry,
More informationAgenda. 1 Opioid Addiction in the United States. Evidence-based treatments for OUD. OUD Treatment: Best Practices. 4 Groups: Our Model
Agenda 1 Opioid Addiction in the United States 2 Evidence-based treatments for OUD OUD Treatment: Best Practices 4 Groups: Our Model 2 Groups is a national network of clinics providing affordable, evidencebased
More informationKurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center
Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Data from the National Vital Statistics System Mortality The age-adjusted rate of drug overdose deaths in the United States
More informationClinical Guidelines for the Pharmacologic Treatment of Opioid Use Disorder
Clinical Guidelines for the Pharmacologic Treatment of Community Behavioral Health (CBH) is committed to working with our provider partners to continuously improve the quality of behavioral healthcare
More informationOverview of Medication Assisted Treatment Methadone, Buprenorphine and Naltrexone
Overview of Medication Assisted Treatment Methadone, Buprenorphine and Naltrexone Alexander Y. Walley, MD, MSc Associate Professor of Medicine Director, Addiction Medicine Fellowship Boston University
More informationSW OREGON OPIOID SUMMIT. Medication Assisted Recovery for Opioid Use Disorder. Gregory S. Brigham, Ph.D. Adapt / SouthRiver CHC / Compass
SW OREGON OPIOID SUMMIT Medication Assisted Recovery for Opioid Use Disorder Gregory S. Brigham, Ph.D. Adapt / SouthRiver CHC / Compass Opioid Agonists Mu (μ) receptors stimulated by opioids causing full
More information(Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines)
Buprenorphine Initiation and Maintenance in Pregnancy (Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines) Assessment The diagnosis of OUD should be confirmed by DSM-5
More informationMethadone and Naltrexone ER
Methadone and Naltrexone ER Laura G. Kehoe, MD, MPH, FASAM Medical Director MGH Substance Use Disorder Bridge Clinic Assistant Professor of Medicine Harvard Medical School Disclosures Neither I nor my
More informationClinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)
Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) For Apple Health clients served Fee-for-Service and through contracted Medicaid Managed Care Organizations Updated January
More informationClinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)
Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) What has changed? Effective January 16, 2018, Coordinated Care will change the requirement for form HCA 13-333 Medication
More informationAcute General Medical and Surgical Admission:
Acute General Medical and Surgical Admission: Managing Substance Use Disorders in Patients Who are Severely Ill Scott Grantham, MD Executive Director, Behavioral Health Saint Francis Health System By the
More informationMethadone and Naltrexone ER
Methadone and Naltrexone ER Laura G. Kehoe, MD, MPH, FASAM Medical Director MGH Substance Use Disorder Bridge Clinic Assistant Professor of Medicine Harvard Medical School Objectives Review Full Opioid
More informationLatest Research on Addiction and Treatment
Latest Research on Addiction and Treatment Joshua D Lee MD MSc joshua.lee@nyumc.org / @DrJoshuaDLee Associate Professor NYU School of Medicine, Department of Population Health Disclosures, LeeJD Grants:
More informationOpioids. October 29, Addiction Medicine Review Course CSAM, Newport Beach, CA
Opioids October 29, 2010 Addiction Medicine Review Course CSAM, Newport Beach, CA Daniel P. Alford, MD, MPH, FACP, FASAM Associate Professor of Medicine Boston University School of Medicine Boston Medical
More informationBuprenorphine as a Treatment Option for Opioid Use Disorder
Buprenorphine as a Treatment Option for Opioid Use Disorder Joji Suzuki, MD Assistant Professor of Psychiatry Harvard Medical School Director, Division of Addiction Psychiatry Brigham and Women s Hospital
More informationIdentification and Treatment of Opioid Use Disorders in Primary Care Settings
Identification and Treatment of Opioid Use Disorders in Primary Care Settings 17th Annual Primary Care Symposium February 24, 2018 Kelly S. Barth, DO Associate Professor, Psychiatry & Internal Medicine
More informationHealth Systems and Addiction: Provider Issues
Health Systems and Addiction: Provider Issues The Emerging Roles of Primary Care Patrick G. O Connor MD, MPH Dan and Amanda Adams Professor of General Medicine Chief, General Internal Medicine Yale University
More informationClass Update: Substance Use Disorders
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationAddiction to Opioids. Marvin D. Seppala, MD Chief Medical Officer
Addiction to Opioids Marvin D. Seppala, MD Chief Medical Officer Mayo Clinic Opioid Conference: Evidence, Clinical Considerations and Best Practice Friday, September 30, 2016 26 y.o. female from South
More informationOpioid Use Issues: All the Players
Opioid Use Issues: All the Players Objectives After review, the participant will be able to: 1) Identify criteria for opioid use disorders Andrew J. McLean, MD, MPH Medical Director, ND Department of Human
More informationClinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction
Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Executive Summary
More informationHospitals Role in Addressing the Opioid Crisis
Hospitals Role in Addressing the Opioid Crisis Webinar 5: Buprenorphine in the Emergency Department November 14, 2017 Agenda Hospital Based Buprenorphine Initiatives Yngvild Olsen, M.D., Medical Consultant,
More informationScreening, Diagnosis, and Medication Assisted Treatment for Alcohol Use Disorders
Psychiatry and Addictions Case Conference Screening, Diagnosis, and Medication Assisted Treatment for Alcohol Use Disorders MARK DUNCAN, MD Acting Assistant Professor, Co-lead University of Washington
More informationManagement of Opioid Use Disorder in Primary Care
1 Northwest ATTC presents Management of Opioid Use Disorder in Primary Care Joseph O. Merrill, MD, MPH University of Washington Associate Professor of Medicine 4/26/2018 Today s Presenter 2 Joseph Merrill,
More informationPrepared by: Dr. Elizabeth Woodward, University of Toronto Resident in Psychiatry
Prepared by: Dr. Elizabeth Woodward, University of Toronto Resident in Psychiatry In broad terms, substance use disorders occur when a substance is used in a compulsive manner with a lack of control over
More informationBuprenorphine is the most effective office-based treatment available for heroin and prescription opioid addiction
Buprenorphine is the most effective office-based treatment available for heroin and prescription opioid addiction The Problem The overdose death rate in Missouri and in the country has been rising for
More informationBuprenorphine for Family Medicine. Hannah Snyder, MD Addiction Medicine Fellow, UCSF 12/7/17
+ Buprenorphine for Family Medicine Hannah Snyder, MD Addiction Medicine Fellow, UCSF 12/7/17 + Disclosures No conflicts of interest Off-label use of medications + Who here: Has taken care of a patient
More informationMedication Assisted Treatment
Meeting the Needs of Your Clients: Building Competencies in Mental Health and Addiction Services Medication Assisted Treatment November 5, 2018 In partnership with: House Keeping Because this is a webinar,
More informationModule II Opioids 101 Opiate Opioid
BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS Module II Opioids 101 Module II Goals of the Module This module reviews the following:! Opioid addiction and the brain!
More informationResponding to the Opioid Epidemic
Responding to the Opioid Epidemic Jessica Gray, MD Addiction Medicine Fellow Boston Medical Center ROME New England August 17, 2017 Disclosures for Jessica Gray, MD No conflicts Learning Objectives Describe
More informationHARM REDUCTION & TREATMENT. Devin Reaves MSW
HARM REDUCTION & TREATMENT Devin Reaves MSW The mission of PAHRC is to promote the health, dignity, and human rights of individuals who use drugs and communities impacted by drug use. Recognizing that
More informationNaltrexone Overview. Todd Korthuis, MD, MPH ECHO-MAT Conference November 7, 2017
Naltrexone Overview Todd Korthuis, MD, MPH ECHO-MAT Conference November 7, 2017 Disclosure Information Speaker/Planner: Todd Korthuis, MD, has nothing to disclose. 2 Pharmacotherapy for Opioid Use Disorder
More informationMedication Assisted Treatment of an Opioid Use Disorder. J. Craig Allen, MD. Medical Director, Rushford
Medication Assisted Treatment of an Opioid Use Disorder J. Craig Allen, MD. Medical Director, Rushford Learning objectives At the conclusion of this activity, participants will be able to: Understand
More informationThe Opioid Crisis: What Can Physicians Do About It?
The Opioid Crisis: What Can Physicians Do About It? Richard S. Schottenfeld, M.D. Professor and Chair, Department of Psychiatry and Behavioral Sciences 2018 Louis J. Kolodner Memorial Lecture Disclosures
More informationMedication Assisted Treatment for Opioid Use Disorders and Veteran Populations
Medication Assisted Treatment for Opioid Use Disorders and Veteran Populations Kamala Greene Genece, Ph.D. VP, Clinical Director Phoenix Houses of New York Benjamin R. Nordstrom, M.D., Ph.D. President
More informationAGENDA U.S. SURGEON GENERAL, VIVEK MURTHY MD 2/5/2019
FORMER U.S. SURGEON GENERAL, VIVEK MURTHY MD AN ESTIMATED 20.8 MILLION PEOPLE IN OUR COUNTRY ARE LIVING WITH A SUBSTANCE USE DISORDER. THIS IS SIMILAR TO THE NUMBER OF PEOPLE WHO HAVE DIABETES, AND 1.5
More informationU.S. SURGEON GENERAL, VIVEK MURTHY MD
FORMER U.S. SURGEON GENERAL, VIVEK MURTHY MD AN ESTIMATED 20.8 MILLION PEOPLE IN OUR COUNTRY ARE LIVING WITH A SUBSTANCE USE DISORDER. THIS IS SIMILAR TO THE NUMBER OF PEOPLE WHO HAVE DIABETES, AND 1.5
More informationMedication Assisted Treatment. MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment
Medication Assisted Treatment MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment Opioid Drugs Opium Morphine Heroin Codeine Oxycodone Roxycodone Oxycontin
More informationROSC & MAT II: Opioid Treatment Services
ROSC & MAT II: Opioid Treatment Services September 23, 2015 Stan DeKemper Executive Director Indiana Credentialing Association on Addiction and Drug Abuse 1 GOALS Review medication assisted recovery Identify
More informationOpioids. Sergio Hernandez, MD
Opioids Sergio Hernandez, MD Required Slide Disclosures 1. SIGNIFICANT FINANCIAL INTERESTS NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT 2. GENERAL AND OBLIGATION INTERESTS All general
More informationTHE NALTREXONE CHALLENGE
THE NALTREXONE CHALLENGE DISCLOSURE Natasha Rodney-Cail, Pharmacist, Drug Evaluation Unit Has no conflicts of interest Maureen Allen Has no conflicts of interest DONNA 68 years old Currently treated with
More informationLong term treatment for opioid dependence Antagonist therapy
Long term treatment for opioid dependence Antagonist therapy Treatment of Opioid Dependence Antagonist treatment Naltrexone Naltrexone (NTX) synthesized in 1965 Eliminate drug carving and prevent relapse
More informationMain Questions. Why study addiction? Substance Use Disorders, Part 1 Alecia Schweinsburg, MA Abnromal Psychology, Fall Substance Use Disorders
Substance Use Disorders Main Questions Why study addiction? What is addiction? Why do people become addicted? What do alcohol and drugs do? How do we treat substance use disorders? Why study addiction?
More informationOpioids Research to Practice
Opioids Research to Practice May 2013 Daniel P. Alford, MD, MPH, FACP, FASAM Associate Professor of Medicine Assistant Dean, Continuing Medical Education Case 32 yo female brought in after heroin overdose
More informationRates of Opioid Overdose Deaths, Sales, and Treatment Admissions: US,
Rates of Opioid Overdose Deaths, Sales, and Treatment Admissions: US, 1999 21 8 Rates of Prescription Painkiller Sales, Deaths, and Substance Abuse Treatment Admissions (1999 21) 7 Rate 6 5 4 3 Sales per
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2009 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationPharmacotherapy for opioid addiction. Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco
Pharmacotherapy for opioid addiction Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco Disclosure slide No commercial conflicts to disclose. Gaps in current treatment of opioid
More informationBuilding capacity for a CHC response to Ontario's Opioid Crisis
Building capacity for a CHC response to Ontario's Opioid Crisis Rob Boyd Oasis Program Director Luc Cormier, RN, MScN Community Health Nurse Sandy Hill Community Health Centre #AOHC2016 @rboyd6 @SandyHillCHC
More informationMedical Assisted Treatment of Opioid
Medical Assisted Treatment of Opioid Dependence with XR-NTX(Vivitrol) Michael McNamara DO, FACN Medical Director Mental Health Center of Greater Manchester Manchester NH Outline Overview of Opioid Dependence
More informationMAT 101: TREATMENT OF OPIOID USE DISORDER
MAT 101: TREATMENT OF OPIOID USE DISORDER WITH SPECIAL EMPHASIS ON BUPRENORPHINE/NALOXONE ICADD May 22, 2018 Alicia Carrasco, MD Debby Woodall, LCSW, ACADC Magni Hamso, MD, MPH Terry Reilly Health Services
More informationMedicated Assisted Treatment
Medicated Assisted Treatment Enhancing the Potential for Recovery Part I Diana Padilla Program Manager NeC-ATTC 2 Diana Padilla, RCR, CASAC-T padilla@ndri.org Diana Padilla is a program manager at NDRI-USA,
More informationOpioid Agonists. Natural derivatives of opium poppy - Opium - Morphine - Codeine
Natural derivatives of opium poppy - Opium - Morphine - Codeine Opioid Agonists Semi synthetics: Derived from chemicals in opium -Diacetylmorphine Heroin - Hydromorphone Synthetics - Oxycodone Propoxyphene
More informationOpioids Research to Practice
Opioids Research to Practice CRIT/FIT 2016 April 2016 Daniel P. Alford, MD, MPH Associate Professor of Medicine Assistant Dean, Continuing Medical Education Director, Clinical Addiction Research and Education
More informationAppendix F Federation of State Medical Boards
Appendix F Federation of State Medical Boards Model Policy Guidelines for Opioid Addiction Treatment in the Medical Office SECTION I: PREAMBLE The (name of board) recognizes that the prevalence of addiction
More informationExtended-Release Naltrexone for Opioid Relapse Prevention
Extended-Release Naltrexone for Opioid Relapse Prevention 1.NYU SOM; Bellevue Hospital Center 2.Brown Univ. 3. Friends Research Institute 4. Columbia Univ. 5. Univ. Pennsylvania 6. Univ. Virginia Funding:
More informationMedication for Addiction Treatment (MAT)
SBIRT Training Screening, Brief Intervention & Referral to Treatment Medication for Addiction Treatment (MAT) The Faith & Spirituality Integrated SBIRT Network Navigating the Training Welcome! These health
More informationMEDICATION ASSISTED TREATMENTS (MAT) FOR SUBSTANCE USE DISORDERS
MEDICATION ASSISTED TREATMENTS (MAT) FOR SUBSTANCE USE DISORDERS PHYLLIS RAYNOR, PHD, PMHNP-BC, APRN CLINICAL ASSISTANT PROFESSOR, USC COLLEGE OF NURSING LEARNING OBJECTIVES: Define types of SUD and purposes
More informationFY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine
FY17 SCOPE OF WORK TEMPLATE Name of Program/Services: Medication-Assisted Treatment: Buprenorphine Procedure Code: Modification of 99212, 99213 and 99214: 99212 22 99213 22 99214 22 Definitions: Buprenorphine
More informationThe Importance of Psychological Treatment and Behavioral Support
The Importance of Psychological Treatment and Behavioral Support Michael W. Otto, PhD Department of Psychological and Brain Science Boston University Conflicts and Acknowledgements No industry funding
More informationNaltrexone Overview. Todd Korthuis, MD, MPH ECHO-MAT Conference February 14, 2017
Naltrexone Overview Todd Korthuis, MD, MPH ECHO-MAT Conference February 14, 2017 Pharmacotherapy for Opioid Use Disorder % Mu Receptor Intrinsic Activity 100 90 80 Full Agonist: Methadone ( How High )
More informationCharles P. O Brien, MD, PhD University of Pennsylvania No financial conflicts, patents, speakers bureaus
Pain & Opioid Epidemic 2018 Charles P. O Brien, MD, PhD University of Pennsylvania No financial conflicts, patents, speakers bureaus Opioids 3400 BC Mesopotamia, Joy plant 1843 morphine by syringe 1874
More informationLinking Opioid Treatment in Primary Care. Roxanne Lewin M.D.
Roxanne Lewin M.D. The Facts Fewer than 10 percent of individuals with an alcohol use disorder and only about 20 percent of individuals with an opioid use disorder receive specialty treatment. Many individuals
More informationNALTREXONE DAVID CRABTREE, MD, MPH UNIVERSITY OF UTAH HEALTH, 2018
NALTREXONE DAVID CRABTREE, MD, MPH TREATMENT OF OPIOID USE DISORDER (OUD) Majority of people who develop OUD are not receiving treatment Only a small fraction of patients are offered treatment with medications
More informationTHA Medication Safety Summit. Wesley Geminn, PharmD, BCPP
THA Medication Safety Summit Wesley Geminn, PharmD, BCPP Current Trends: Overdose Deaths in 2017 72,000 Or 197 per day 8 per hour National Opioid Overdose Statistics https://www.drugabuse.gov/related-topics/trendsstatistics/overdose-death-rates
More informationOpioid Use Disorders as a Brain Disease Why MAT is so important. Ron Jackson, M.S.W., L.I.C.S.W.
Opioid Use Disorders as a Brain Disease Why MAT is so important Ron Jackson, M.S.W., L.I.C.S.W. Affiliate Professor School of Social Work University of Washington Organization Name: CareOregon Course Title:
More informationTreatment of Opioid Use Disorder
Treatment of Opioid Use Disorder Casia Horseman, MD Assistant Professor Department of Psychiatry and Behavioral Health The Ohio State University Wexner Medical Center Objectives Discuss the historical
More informationTreatment of Opioid Use Disorder
Treatment of Opioid Use Disorder Casia Horseman, MD Assistant Professor Department of Psychiatry and Behavioral Health The Ohio State University Wexner Medical Center Objectives Discuss the historical
More informationMEDICATION ASSISTED TREATMENT
MEDICATION ASSISTED TREATMENT MODULE 14 ALLIED TRADES ASSISTANCE PROGRAM PREVENTATIVE EDUCATION: SUBSTANCE USE DISORDER Medication Assisted Treatment Types of Medication Assisted Treatment: Methadone Naltrexone
More informationClosing the Loop in Treating Opioid Addiction:
Closing the Loop in Treating Opioid Addiction: Integrating MAT into Prison and Jail Health Systems May 9, 2018 Webinar Housekeeping All lines are muted This session will be recorded To ask a question:
More informationResponding to the Opioid Epidemic: Behavioral Health Specialists Role on the Interprofessional Team
Responding to the Opioid Epidemic: Behavioral Health Specialists Role on the Interprofessional Team Cheryl L Mejta, Ph.D. Nancy H Burley, Ed.D. Serena Wadhwa, Psy. D., LCPC, RYT, CADC Objectives Identify
More informationMedications for Opioid Use Disorder. Charles Brackett, MD, MPH General Internal Medicine, DHMC
Medications for Opioid Use Disorder Charles Brackett, MD, MPH General Internal Medicine, DHMC Opioid Related Deaths are on the Rise in the US National Vital Statistics System Mortality File Deaths are
More information7/7/2016 Journal of the American Medical Association,
1 2 Journal of the American Medical Association, 2008 3 The Clinical Trial 152 Adolescents and Young Adults (Age 15 to 21) randomly assigned to either; 1. 2 weeks of Buprenorphine detox 2. 12 weeks of
More informationTHE STATE OF MEDICINE IN ADDICTION RECOVERY
OVERVIEW: Review addiction stats and trends Define addiction Explain neurobiology of addiction Review treatments of addiction Addiction Definition: A Primary, chronic, relapsing disease of brain reward,
More informationInterdisciplinary Management of Opioid Use Disorder in Rural Primary Care Settings
Interdisciplinary Management of Opioid Use Disorder in Rural Primary Care Settings BRIAN GARVEY, MD, MPH REBECCA CANTONE, MD OREGON HEALTH & SCIENCE UNIVERSITY SCAPPOOSE RURAL HEALTH CENTER Disclosures
More informationClass Update: Substance Use Disorders
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationOverview of Opioid Use Disorder
Overview of Opioid Use Disorder Doug Burgess, MD Medical Director of Outpatient Services, Truman Medical Centers Assistant Professor of Psychiatry, University of Missouri- Kansas City Objectives History
More informationALCOHOL USE DISORDER WITHDRAWAL MANAGEMENT AND LONG TERM TREATMENT ANA HOLTEY, MD ADDICTION MEDICINE FELLOW UNIVERSITY OF UTAH HEALTH
ALCOHOL USE DISORDER WITHDRAWAL MANAGEMENT AND LONG TERM TREATMENT ANA HOLTEY, MD ADDICTION MEDICINE FELLOW UNIVERSITY OF UTAH HEALTH Prevalence of 12-Month Alcohol Use, High-Risk Drinking, and DSM-IV
More informationWhat Is Heroin? Examples of Opioids. What Science Says about Opioid Use Disorder and Its Treatment 6/27/2016
What Science Says about Opioid Use Disorder and Its Treatment Perilou Goddard, Ph.D. Department of Psychological Science Northern Kentucky University Examples of Opioids Agonists (activate opioid receptors)
More informationMedication-Assisted Treatment (MAT) for Opioid Use Disorders
Medication-Assisted Treatment (MAT) for Opioid Use Disorders Sybil Marsh MA MD FASAM Department of Family Medicine and Community Health Case Western Reserve University/UHCMC Learning Objective 1 Following
More informationRestoration of Parenting Ability Through Treatment for Substance Use Disorders
Restoration of Parenting Ability Through Treatment for Substance Use Disorders DEBRA M. BARNETT, MD Board Certified in General Psychiatry, Addiction Psychiatry, Geriatric Psychiatry, and Forensic Psychiatry
More informationTreating Opioid Use Disorders: An Update for Counselors and Other Providers
Treating Opioid Use Disorders: An Update for Counselors and Other Providers Brad Shapiro, MD Medical Director Opiate Treatment Outpatient Program Zuckerberg San Francisco General THE DOSING WINDOW HISTORICAL
More informationPsychosocial Treatments for Opioid Use Disorder Overview
Psychosocial Treatments for Opioid Use Disorder Overview Nalan Ward, MD Director Outpatient Addiction Services Department of Psychiatry Massachusetts General Hospital *Images used for educational purposes
More informationSAFE PRESCRIBING: RULES AND REGULATIONS. Michelle Y. Owens, MD MS State Board of Medical Licensure June 30, 2017
SAFE PRESCRIBING: RULES AND REGULATIONS Michelle Y. Owens, MD MS State Board of Medical Licensure June 30, 2017 DISCLOSURES I have no financial disclosures. OBJECTIVES Discuss the significance of the opiate
More informationTreatment Approaches for Drug Addiction
Treatment Approaches for Drug Addiction NOTE: This fact sheet discusses research findings on effective treatment approaches for drug abuse and addiction. If you re seeking treatment, you can call the Substance
More informationMedication Assisted Treatment as an alternative in Drug Courts*
Medication Assisted Treatment as an alternative in Drug Courts* National Drug Court Institute *portions of this presentation include adapted slides by Frances Levin, MD, Joshua Lee, MD, & Laurence Westreich,
More informationMedication-Assisted Treatment (MAT) Overview
Medication-Assisted Treatment (MAT) Overview 2014 Opiate Conference: Don t Get Me Started Hyatt Regency, Columbus, Ohio June 30-July 1, 2014 Christina M. Delos Reyes, MD Medical Consultant, Center for
More information